Case Report
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Aug 26, 2021; 9(24): 7189-7195
Published online Aug 26, 2021. doi: 10.12998/wjcc.v9.i24.7189
Aspirin-induced long-term tumor remission in hepatocellular carcinoma with adenomatous polyposis coli stop-gain mutation: A case report
Qu Lin, Ming-Jun Bai, Hao-Fan Wang, Xiang-Yuan Wu, Ming-Sheng Huang, Xing Li
Qu Lin, Xiang-Yuan Wu, Xing Li, Department of Medical Oncology and Guangdong Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, Guangdong Province, China
Ming-Jun Bai, Hao-Fan Wang, Ming-Sheng Huang, Department of Intervention and Guangdong Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, Guangdong Province, China
Author contributions: Lin Q and Huang MS recruited the patient and made clinical decisions; Bai MJ and Wang HF carried out the follow up; Li X, Wang HF and Bai MJ performed the image analysis; Li X performed the molecular analysis; Lin Q, Huang MS, Wu XY and Li X carried out the molecular pathway analysis; Li X wrote the manuscript; Huang MS is the co-corresponding author.
Supported by Guangzhou Science and Technology Project, No. 201904010461; and Major Talents Project of Guangdong Province, No. 2019TQ05Y266.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xing Li, MD, Professor, Department of Medical Oncology and Guangdong Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, No. 600 Tianhe Road, Guangzhou 510630, Guangdong Province, China. lixing9@mail.sysu.edu.cn
Received: February 1, 2021
Peer-review started: February 1, 2021
First decision: March 7, 2021
Revised: April 6, 2021
Accepted: May 18, 2021
Article in press: May 18, 2021
Published online: August 26, 2021
Core Tip

Core Tip: Hepatocellular carcinoma (HCC) is a highly heterogeneous disease. Due to the differences in etiology and ethnicities, the driving genes in HCC are likely to be different globally. Adenomatous polyposis coli (APC) mutations are critical in a fraction of HCC patients, as APC mutations might trigger HCC by activating the Wnt pathway. The effects of this mutation could be consistently suppressed by aspirin. Thus, APC mutation-triggered HCC might be a new subgroup of chronic hepatitis B virus infection-related HCC. Wnt pathway inhibition could be an effective remedy for this subgroup of patients.